Abstract
Sprycel® (dasatinib) film-coated tablet is a new medicinal product that was recently launched for the treatment of chronic myelogenous leukemia. Due to the early success of dasatinib in phase I clinical trials, development activities were accelerated significantly to enable wide distribution of this drug to patients. As a BCS class II compound, dissolution was considered a critical quality attribute of dasatinib film-coated tablets and a discriminating dissolution method was required to support tablets intended for Phase II clinical trials and commercial use. A systematic experimental approach was established to rapidly screen media pH, solubility enhancers, and concentration in order to overcome the challenges of a tight timeline and limited study materials. The final validated method utilizes 1,000 mL of pH 4.0 acetate buffer with 1% Triton X-100 with a USP Apparatus II (paddle) rotating at 60 rpm and a HPLC sample analysis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
